Herpes Simplex Virus (HSV) is a common viral infection that leads to the development of blisters and sores, most frequently around the mouth (oral herpes) or in the genital region (genital herpes). The infection is caused by two virus types: HSV-1 and HSV-2. Although the virus can remain dormant in the body for extended periods, it can reactivate under specific conditions, resulting in recurrent outbreaks. Despite its widespread nature, there is a continued need for more effective antiviral therapies that can minimize outbreak frequency and improve patients’ quality of life.

From prevalence to pipeline—our infographic breaks it down!: Click Here

Herpes Simplex Epidemiological Segmentation

The epidemiological segmentation of Herpes Simplex across the 7MM from 2020 to 2034 includes:

• Total seroprevalent cases of HSV
  
• Total symptomatic cases of HSV
  
• Total diagnosed cases of HSV
  
• Gender-specific diagnosed cases of HSV
  
• Total recurrent cases of HSV
  

Herpes Simplex Epidemiology

In 2023, Herpes Simplex showed notable prevalence trends across the 7MM:

• Around 13.04 million diagnosed cases of HSV were recorded in the 7MM, including approximately 4.95 million in the United States. This number is projected to decline throughout the forecast period.
  
• Diagnosed cases among females were higher than in males across the 7MM, with women accounting for roughly 55% of the total diagnosed cases.
  
• In Japan, an estimated 1.56 million diagnosed cases of HSV were reported in 2023—comprising 700,000 male cases and 856,000 female cases. These figures are also expected to decrease over time.

Numbers tell part of the story—get the full analysis in our report: Click Here

Herpes Simplex Market

The total market size for Herpes Simplex in the 7MM was valued at approximately USD 3.1 billion in 2023.

Herpes Simplex Market Drivers

• The advancement of new antiviral therapies such as PRITELIVIR (AIC-316) and mRNA-1608 represents promising developments in improving HSV management and reducing the recurrence of outbreaks.
  
• Growing awareness and improvements in diagnostic technologies are anticipated to support better identification and treatment of symptomatic HSV cases, thereby fueling market expansion.
  

Herpes Simplex Market Barriers

• The unpredictable nature of HSV outbreaks and varied treatment responses complicate disease management and the development of uniform therapeutic approaches.
  
• Limited access to and the high cost of novel antiviral drugs may hinder their widespread use, particularly in low-resource settings, thus posing a challenge to market growth.
  

Herpes Simplex Emerging Therapies

• PRITELIVIR (AIC-316)
  
• GSK3943104
  
• mRNA-1608
  
• And others
  

Herpes Simplex Key Players

• AiCuris Anti-infective Cures AG
  
• GlaxoSmithKline
  
• ModernaTX, Inc.
  
• And others

Grab your free copy of the infographic—essential for any analyst!: Click Here